Malignant melanoma

被引:11
|
作者
Lodde, Georg [1 ]
Zimmer, Lisa [1 ]
Livingstone, Elisabeth [1 ]
Schadendorf, Dirk [1 ,2 ,3 ]
Ugurel, Selma [1 ]
机构
[1] Univ Klinikum Essen, Klin & Poliklin Dermatol Venerol & Allergol, Hufelandstr 55, D-45147 Essen, Germany
[2] DKTK, Partnerstandort Essen, Essen, Germany
[3] Deutsch Krebsforschungszentrum DKFZ Heidelberg, Heidelberg, Germany
来源
HAUTARZT | 2020年 / 71卷 / 01期
关键词
Skin neoplasms; Nevi and melanomas; Ultraviolet rays; Sentinel lymph node biopsy; Margins of excision; DABRAFENIB PLUS TRAMETINIB; AMERICAN JOINT COMMITTEE; STAGE-III; ADJUVANT IPILIMUMAB; METASTATIC MELANOMA; CUTANEOUS MELANOMA; DOUBLE-BLIND; 10; MG/KG; SURVIVAL; CANCER;
D O I
10.1007/s00105-019-04514-0
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Malignant melanoma is an aggressive skin cancer that originates from cells of the melanocytic lineage and is associated with an invasive growth pattern and early spread. Besides endogenous risk factors such as fair skin type or genetic disposition for the formation of multiple nevi, exposure to ultraviolet light is the most important exogenous risk factor. Treatment of patients with primary tumors includes the complete excision of the primary lesion with appropriate safety margins and in patients with an increased risk of metastasis sentinel lymph node excision. Prognostically significant parameters are the Breslow invasion depth, ulceration of the primary lesion, and sentinel lymph node status. Systemic therapy plays an important role in the adjuvant setting and for inoperable tumors. Depending on the indication and the molecular profile of the tumor tissue, immune checkpoint inhibitors or targeted kinase inhibitors can be used and may result in a significant prolongation of survival times.
引用
收藏
页码:63 / 75
页数:13
相关论文
共 50 条
  • [1] Malignant melanoma: Classification and staging of malignant melanoma
    Eigentler, TK
    Garbe, C
    [J]. CONTROVERSIES IN THE TREATMENT OF SKIN NEOPLASIAS, 2005, 39 : 149 - 158
  • [2] Malignant melanoma The role of BRAF inhibition in malignant melanoma
    Zaremba, A.
    Zimmer, L.
    Griewank, K. G.
    Ugurel, S.
    Roesch, A.
    Schadendorf, D.
    Livingstone, E.
    [J]. ONKOLOGE, 2020, 26 (08): : 713 - 720
  • [3] MALIGNANT MELANOMA RATHER THAN MALIGNANT CUTANEUS MELANOMA?
    Consolo, P.
    Crino, S. F.
    Pallio, S.
    Scalisi, G.
    Giacobbe, G.
    Tortora, A.
    [J]. DIGESTIVE AND LIVER DISEASE, 2015, 47 : E112 - E112
  • [4] Malignant melanoma - Markers for progression and prognosis in malignant melanoma
    Geilen, CC
    Georgieva, J
    Milling, A
    Farthmann, B
    [J]. CONTROVERSIES IN THE TREATMENT OF SKIN NEOPLASIAS, 2005, 39 : 120 - 126
  • [5] Malignant melanoma rather than malignant cutaneous melanoma?
    Crino, Stefano F.
    Scalisi, Giuseppe
    Pallio, Socrate
    Giacobbe, Giuseppa
    Cintolo, Marcello
    Consolo, Pierluigi
    [J]. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2013, 25 (04) : 503 - 506
  • [6] MALIGNANT MELANOMA
    OGLESBY, CD
    [J]. AMERICAN JOURNAL OF OPHTHALMOLOGY, 1964, 58 (01) : 136 - &
  • [7] MALIGNANT MELANOMA
    不详
    [J]. LANCET, 1955, 2 (SEP10): : 545 - 546
  • [8] MALIGNANT MELANOMA
    COSTELLO, MJ
    [J]. ARCHIVES OF DERMATOLOGY, 1957, 76 (04) : 527 - 527
  • [9] MALIGNANT MELANOMA
    NIEDELMAN, ML
    [J]. AMA ARCHIVES OF DERMATOLOGY AND SYPHILOLOGY, 1950, 62 (05): : 765 - 766
  • [10] MALIGNANT MELANOMA
    COSTELLO, J
    [J]. ARCHIVES OF DERMATOLOGY, 1957, 75 (04) : 614 - 615